FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022334115> ?p ?o ?g. }

• W2022334115 endingPage "148" @default.
• W2022334115 startingPage "142" @default.
• W2022334115 abstract "Objectives Uterine serous carcinoma (USC) represents an aggressive variant of endometrial cancer and accounts for a large proportion of deaths annually. HER2/neu amplification is associated with USC in approximately 30–35% of cases. The objective of this study was to determine the sensitivity of a panel of primary USC cell lines to the small tyrosine kinase inhibitor neratinib, an ErbB1 and HER2 inhibitor, both in vitro and in vivo. Methods HER2/neu amplification was determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in 24 USC cell lines. Flow cytometry was used to determine the effects of neratinib on cell viability, cell cycle distribution and signaling in vitro. Mice harboring HER2/neu amplified xenografts were treated with neratinib to assess the efficacy of the drug in vivo. Results HER2/neu amplification was noted in 8/24 primary cell lines. Data regarding the efficacy of neratinib was determined using 4 HER2 amplified cell lines and 4 non-amplified cell lines with similar growth rates. Data revealed that cell lines with HER2/neu amplification were exquisitely more sensitive to neratinib compared to non-amplified cell lines (mean ± SEM IC50: 0.011 μM ± 0.0008 vs. 0.312 μM ± 0.0456 p < 0.0001). Neratinib caused arrest in the G0/G1 phase of the cell cycle and resulted in decreased autophosphorylation of HER2 and activation of S6. Neratinib treated mice harboring xenografts of HER2/neu amplified USC showed delayed tumor growth and improved overall survival compared to vehicle (p = 0.0019). Conclusions Neratinib may be a potential treatment option for patients harboring HER2/neu amplified USC. Clinical trials for this subset of endometrial cancer patients are warranted." @default.
• W2022334115 created "2016-06-24" @default.
• W2022334115 creator A5008166734 @default.
• W2022334115 creator A5010339370 @default.
• W2022334115 creator A5026827320 @default.
• W2022334115 creator A5029807655 @default.
• W2022334115 creator A5035381883 @default.
• W2022334115 creator A5041993659 @default.
• W2022334115 creator A5045925318 @default.
• W2022334115 creator A5046857977 @default.
• W2022334115 creator A5052390359 @default.
• W2022334115 creator A5066823675 @default.
• W2022334115 date "2014-10-01" @default.
• W2022334115 modified "2023-09-28" @default.
• W2022334115 title "Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo" @default.
• W2022334115 cites W1597931794 @default.
• W2022334115 cites W1974024530 @default.
• W2022334115 cites W1984069313 @default.
• W2022334115 cites W1984136423 @default.
• W2022334115 cites W1994381471 @default.
• W2022334115 cites W1997025193 @default.
• W2022334115 cites W2028878627 @default.
• W2022334115 cites W2035574196 @default.
• W2022334115 cites W2045755077 @default.
• W2022334115 cites W2047531307 @default.
• W2022334115 cites W2050156776 @default.
• W2022334115 cites W2064416108 @default.
• W2022334115 cites W2065607022 @default.
• W2022334115 cites W2070011883 @default.
• W2022334115 cites W2074730236 @default.
• W2022334115 cites W2080384716 @default.
• W2022334115 cites W2084234145 @default.
• W2022334115 cites W2114195503 @default.
• W2022334115 cites W2118224996 @default.
• W2022334115 cites W2118925298 @default.
• W2022334115 cites W2136701318 @default.
• W2022334115 cites W2149952977 @default.
• W2022334115 cites W2154246971 @default.
• W2022334115 cites W2168730865 @default.
• W2022334115 cites W2172265576 @default.
• W2022334115 doi "https://doi.org/10.1016/j.ygyno.2014.08.006" @default.
• W2022334115 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25124161" @default.
• W2022334115 hasPublicationYear "2014" @default.
• W2022334115 type Work @default.
• W2022334115 sameAs 2022334115 @default.
• W2022334115 citedByCount "29" @default.
• W2022334115 countsByYear W20223341152014 @default.
• W2022334115 countsByYear W20223341152015 @default.
• W2022334115 countsByYear W20223341152016 @default.
• W2022334115 countsByYear W20223341152017 @default.
• W2022334115 countsByYear W20223341152018 @default.
• W2022334115 countsByYear W20223341152019 @default.
• W2022334115 countsByYear W20223341152020 @default.
• W2022334115 countsByYear W20223341152021 @default.
• W2022334115 countsByYear W20223341152022 @default.
• W2022334115 countsByYear W20223341152023 @default.
• W2022334115 crossrefType "journal-article" @default.
• W2022334115 hasAuthorship W2022334115A5008166734 @default.
• W2022334115 hasAuthorship W2022334115A5010339370 @default.
• W2022334115 hasAuthorship W2022334115A5026827320 @default.
• W2022334115 hasAuthorship W2022334115A5029807655 @default.
• W2022334115 hasAuthorship W2022334115A5035381883 @default.
• W2022334115 hasAuthorship W2022334115A5041993659 @default.
• W2022334115 hasAuthorship W2022334115A5045925318 @default.
• W2022334115 hasAuthorship W2022334115A5046857977 @default.
• W2022334115 hasAuthorship W2022334115A5052390359 @default.
• W2022334115 hasAuthorship W2022334115A5066823675 @default.
• W2022334115 hasConcept C121608353 @default.
• W2022334115 hasConcept C126322002 @default.
• W2022334115 hasConcept C142724271 @default.
• W2022334115 hasConcept C150903083 @default.
• W2022334115 hasConcept C203014093 @default.
• W2022334115 hasConcept C207001950 @default.
• W2022334115 hasConcept C2778820342 @default.
• W2022334115 hasConcept C2779413316 @default.
• W2022334115 hasConcept C2779786085 @default.
• W2022334115 hasConcept C502942594 @default.
• W2022334115 hasConcept C530470458 @default.
• W2022334115 hasConcept C54355233 @default.
• W2022334115 hasConcept C553184892 @default.
• W2022334115 hasConcept C71924100 @default.
• W2022334115 hasConcept C81885089 @default.
• W2022334115 hasConcept C86803240 @default.
• W2022334115 hasConceptScore W2022334115C121608353 @default.
• W2022334115 hasConceptScore W2022334115C126322002 @default.
• W2022334115 hasConceptScore W2022334115C142724271 @default.
• W2022334115 hasConceptScore W2022334115C150903083 @default.
• W2022334115 hasConceptScore W2022334115C203014093 @default.
• W2022334115 hasConceptScore W2022334115C207001950 @default.
• W2022334115 hasConceptScore W2022334115C2778820342 @default.
• W2022334115 hasConceptScore W2022334115C2779413316 @default.
• W2022334115 hasConceptScore W2022334115C2779786085 @default.
• W2022334115 hasConceptScore W2022334115C502942594 @default.
• W2022334115 hasConceptScore W2022334115C530470458 @default.
• W2022334115 hasConceptScore W2022334115C54355233 @default.
• W2022334115 hasConceptScore W2022334115C553184892 @default.
• W2022334115 hasConceptScore W2022334115C71924100 @default.
• W2022334115 hasConceptScore W2022334115C81885089 @default.

• next